for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aurinia Pharmaceuticals Inc

AUP.TO

Latest Trade

6.16CAD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

4.70

 - 

10.47

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
6.16
Open
--
Volume
--
3M AVG Volume
0.72
Today's High
--
Today's Low
--
52 Week High
10.47
52 Week Low
4.70
Shares Out (MIL)
94.29
Market Cap (MIL)
514.27
Forward P/E
-6.11
Dividend (Yield %)
--

Latest Developments

More

Aurinia Reports Q2 2019 Results

Aurinia Pharmaceuticals Inc Qtrly Loss Per Share $0.14

Iljin SNT Co Says Now "Seriously Considering" Whether To Nominate New Directors To Aurinia's Board

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Industry

Biotechnology & Drugs

Contact Info

1203-4464 Markham St

+1.250.7084272

https://www.auriniapharma.com

Executive Leadership

George M. Milne

Executive Chairman of the Board

Peter S. Greenleaf

Chief Executive Officer, Director

Dennis Bourgeault

Chief Financial Officer, Corporate Secretary

Michael R. Martin

Chief Operating Officer

Neil Solomons

Chief Marketing Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.660

2017

-0.920

2018

-0.760

2019(E)

-0.673
Price To Earnings (TTM)
--
Price To Sales (TTM)
839.50
Price To Book (MRQ)
3.01
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.33
LT Debt To Equity (MRQ)
0.23
Return on Investment (TTM)
-39.95
Return on Equity (TTM)
-38.40

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up